DNAnexus Completes $68 Million Financing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Feb 6, 2019--DNAnexus, Inc., the leader in biomedical informatics and data management, today announced closing a $68 million financing. The funds were raised from existing investors, GV (formerly Google Ventures), Foresite Capital, TPG Biotech, WuXi NextCODE, and Claremont Creek Ventures, as well as debt and equity financing from Innovatus Capital Partners, LLC.
“DNAnexus has changed how global biomedical research and development markets manage their data and infrastructures,” commented Claes Ekstrom, Managing Director at Innovatus. “We are excited to support DNAnexus’ ongoing mission to accelerate science and medical discoveries by democratizing access to data through a global network.”
The financing supports the deployment of DNAnexus Apollo ™, an advanced platform for multi-omics and clinical data exploration, analysis, and discovery. The Apollo Platform uses the DNAnexus global network, providing secure and compliant infrastructure with access to tools and datasets within a collaborative environment. DNAnexus supports some of the largest human genome sequencing projects in the world, including NIH’s , St. Jude Cloud, AstraZeneca’s 2-million genome initiative, and the Regeneron-Geisinger collaboration.
“The financing enables further development of our translational research solutions, as well as continued growth in genomics with cloud-based solutions for research, clinical diagnostics, and clinical trials,” said Richard Daly, Chief Executive Officer at DNAnexus. “The next wave of biomedical insights will be derived from cross-institutional collaborations that generate massive volumes of clinical and multi-omics data. We are proud of our work dedicated to improving how global research and development organizations leverage large biomedical datasets to develop and deliver precision medicine solutions.”
DNAnexus, the leader in biomedical informatics and data management, has created the global network for genomics and other biomedical data, operating in 33 countries including North America, Europe, China, Australia, South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.
About Innovatus Capital Partners
Innovatus adheres to an investment strategy that identifies disruptive and growth opportunities across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. The Firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. Innovatus and its principals have significant experience providing debt financing to medical device, diagnostics, and biotechnology companies that address unmet medical needs, improve patient outcomes, and reduce overall healthcare expenditures. Further information can be found at innovatuscp.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190206005088/en/
CONTACT: Media Contact:
CG Life for DNAnexus
Mark Button, 408-310-2168
firstname.lastname@example.orgAlyssa Salela, 630-935-6369
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY GENETICS OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: DNAnexus, Inc.
Copyright Business Wire 2019.
PUB: 02/06/2019 08:00 AM/DISC: 02/06/2019 08:01 AM